A gene discovered by researchers at the University of North Carolina at Chapel Hill School of Medicine has been associated with two forms of pancreatic cancer, according to a study by an international group of researchers.

Findings explain why certain patients suffer blood clots from thalidomide; and why aspirin works as an intervention.

In a study of more than 36,000 women, researchers observed that smokers can reduce their risk of developing lung cancer by being physically active. However, they strongly caution that any relative benefit is dwarfed by the benefits gained from quitting smoking.

More than 90 percent of children and young adults who survive five years or longer after diagnosis and treatment for acute myeloid leukemia (AML) are alive 20 years later and leading productive lives, according to a University of Minnesota study.

A new report by leading experts in monoclonal antibody research for oncology offers a conceptual framework for future research in the design of antibody therapies against solid tumors.

Cancer immunoresistance may be partially due to loss of a well-known tumor suppressor gene, according to new research led by Andrew T. Parsa, MD, PhD, assistant professor of neurological surgery at the University of California, San Francisco.

Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.

The International Myeloma Foundation (IMF) conducting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians today noted that multiple studies presented at the 2006 Annual Meeting of the American Society of Hematology (ASH) illustrate the breadth of the gains being made in the treatment of multiple myeloma and related blood cancers.

Common blood pressure medications might help block the spread of pancreatic cancer, researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have found.

By training professionals in high-biodiversity regions to advance the drug discovery process in-country, a novel program drives drug discovery costs down as it promotes tropical biodiversity conservation. An international team describes a successful test of the program in Panama in the December, 2006 issue of BioScience.

Sildenafil and other "impotence drugs" that boost the production of a gassy chemical messenger to dilate blood vessels and produce an erection now also show promise in unmasking cancer cells so that the immune system can recognize and attack them, say scientists at the Johns Hopkins Kimmel Cancer Center.

In five years Gleevec, the little yellow pill, has proved itself to be a miracle drug for most patients who take it.